Results showed that patients with higher expressions of PARP10 were significantly associated with poorer OS and EFS compared to patients with lower expressions of PARP10 (OS: median: 0.88 vs. 2.19 years; P = 0.001; EFS: median: 0.65 vs. 1.12 years; P = 0.041), while the expression of PARP6 showed no influence on the prognosis of AML patients (Figure 2 and Supplementary Figure 4). This evidence concerns the gene PARP10 and acute myeloid leukemia.